FDA Seeks Ways to Guide Online Health Content

BY ALICIA AULT

At a meeting convened by the Food and Drug Administration, pharmaceutical and medical device manufacturers, advertisers, medical Web site owners, search engine companies, and consumer advocates all argued for greater regulation of health-specific content on the Internet, including social media sites.

The agency was seeking opinions on how it could guide health-related communications and promotions for YouTube, Twitter, blogging, and social networking sites. Notably, there were no speakers from any medical society or health care provider organization.

The FDA has not said when it might issue guidance, but it will continue to accept comments until Feb. 28, 2010, said Thomas W. Abrams, director of the FDA Center for Drug Evaluation and Research's division of drug marketing, advertising, and communications.

All speakers agreed that consumers and health care providers increasingly rely on the Internet for information about drugs, devices, and specific conditions, and also to forge communities to share everything from caregiving recommendations to tips on how to perform a knee replacement.

All also agreed that there is a huge amount of inaccurate and misleading information and that it has a great potential for harm—to patients and their families, to health care providers, and to industries seeking credibility. Even as they seek to be the go-to place for accurate, scientific information, drug and device makers said they are wary—of social media in particular—because of the lack of FDA guidance.

Consumer groups raised the specter of pharmaceutical or device companies putting out purely promotional information that glosses over FDA rules requiring a fair balance of risks and benefits.

Michele Sharp, senior director of United States Regulatory Affairs at Eli Lilly, said the company "had avoided significant interactions with providers and patients online" because of FDA's lack of clarity.

"We're looking to the FDA to provide leadership," Ms. Sharp said.

Jeffrey K. Francer, assistant general counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA), said that "the FDA should facilitate manufacturers' communication of important medical information about their products in a responsible way, taking advantage of the same technologies that the FDA and the White House use, including blogs, video, search, and social networking sites such as Twitter."

PhRMA has proposed that posts on Twitter or blogs or other social media sites be accompanied by an official logo that would signify that the information was officially sanctioned by the FDA. Tweets, which are limited to 140 characters, could provide a hyperlink to the full risk and benefit information, Mr. Francer said.

He and other industry representatives said they wanted FDA to review information and promotional materials before they were posted on the Web. This would be a departure from current policy where only a small fraction of print or broadcast materials are reviewed in advance.

Consumer advocate Diana Zuckerman, Ph.D., said she believed that the FDA has historically done a poor job of monitoring direct-to-consumer promotions and going after violators. The agency will be even more challenged in an environment where information can be changed hourly, said Dr. Zuckerman, president of the Washington-based National Research Center for Women and Families. But, she said, the FDA must monitor the Internet and social media. "Realistically the FDA would need a lot more resources to do that," she acknowledged. ■

See page 7

Skin & Allergy News

President, IMNG Alan J. Imhoff

Editor in Chief Mary Jo M. Dales
Executive Editors Denise Fulton, Kathy Scarbeck
Managing Editor Amy Pfeiffer
Deputy Managing Editor Richard Franki
Senior Editors Christina Chase, Kathryn DeMott, Lori Buckner Farmer, Joyce Frieden, Catherine Hackett, Keith Haglund, Gina L. Henderson, Sally Koch Kubetin, Teresa Lassman, Mark S. Lesney, Jane Salodof MacNeil, Catherine Cooper Nellist, Calvin Pierce, Terry Rudd, Elizabeth Wood
Associate Editors Felicia Rosenblatt Black, Therese Borden, Lorinda Bullock, Jay C. Cherniak, Virginia Ingram-Wells, Jane Locastro, Renée Matthews, Carol Nicotera-Ward, Leanne Sullivan
Reporters *Chicago:* Patrice Wendling; *Denver:* Bruce Jancin; *London:* Jonathan Gardner; *Los Angeles:* Betsy Bates; *Miami:* Damian McNamara; *Mid-Atlantic:* Michele G. Sullivan; *New England:* Diana Mahoney; *New York:* Mary Ellen Schneider; *Philadelphia:* Mitchel L. Zoler; *San Diego:* Doug Brunk; *San Francisco:* Sherry Boschert, Robert Finn; *Washington:* Alicia Ault, Jeff Evans, Elizabeth Mechcatie, Heidi Splete, Miriam E. Tucker, Kerri Wachter
Contributing Writers Christine Kilgore, Mary Ann Moon
Project Manager Susan D. Hite
Assignments Manager Megan Evans

Address Changes Fax change of address (with old mailing label) to 973-290-8245 or e-mail change to subs@elsevier.com
Editorial Offices 5635 Fishers Lane, Suite 6000, Rockville, MD 20852, 877-524-9336, sknews@elsevier.com
Reprints Call 240-221-2419

Director of Information Technology Doug Sullivan
Senior Systems Administrators Lee J. Unger, Kreg M. Williams
Systems Administrator/Application Support Peter Ayinde
Accounts Payable Coordinator Daniela Silva

Executive Director, Operations Jim Chicca
Director, Production/Manufacturing Yvonne Evans
Production Manager Judi Sheffer
Production Specialists Anthony Draper, Rebecca Slebodnik
Creative Director Louise A. Koenig
Design Supervisor Elizabeth Byrne Lobdell
Senior Designer Sarah L.G. Breeden
Designer Lisa M. Marfori
Photo Editor Catherine Harrell

Sales Director, IMNG
Mark E. Altier, 973-290-8220, m.altier@elsevier.com
National Account Manager
Sally Cioci, 973-290-8215, fax 973-290-8250, s.cioci@elsevier.com
Advertising Offices
60 Columbia Rd., Bldg. B, 2nd flr., Morristown, NJ 07960, 973-290-8200, fax 973-290-8250
Classified Sales Manager, IMNG
Robert Zwick 973-290-8226, fax 973-290-8250, r.zwick@elsevier.com
Classified Advertising Manager
Andrea LaMonica, 800-381-0569, fax 914-381-0573, a.lamonica@elsevier.com
Classified Advertising Offices
1120 Jensen Avenue, Mamaroneck, NY 10543, 800-381-0569

Program Manager, Customized Publications Malika Wicks
Circulation Analyst Barbara Cavallaro, 973-290-8253, b.cavallaro@elsevier.com
Associate Program Manager Jennifer Eckert
Business Controller Dennis Quirk
Adv. Services Manager Joan Friedman
Credit Supervisor Patricia H. Ramsey
Manager, Admin./Conventions Lynne Kalish
Receptionist Linda Wilson

SKIN & ALLERGY NEWS is an independent newspaper that provides the practicing dermatologist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice.

The ideas and opinions expressed in SKIN & ALLERGY NEWS do not necessarily reflect those of the Publisher. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

POSTMASTER Send changes of address (with old mailing label) to SKIN & ALLERGY NEWS Circulation, 60 Columbia Rd., Bldg. B, 2nd flr., Morristown, NJ 07960.

SKIN & ALLERGY NEWS (ISSN 0037-6337) *is published monthly by Elsevier Inc., 60 Columbia Rd., Bldg. B, 2nd flr., Morristown, NJ 07960, 973-290-8200, fax 973-290-8250. Subscription price is $103.00 per year. Periodicals postage paid at Morristown, NJ, and additional offices.*

Founding Publisher: Jack O. Scher
Founding Editor: William Rubin

INTERNATIONAL MEDICAL NEWS GROUP

BPA

VITAL SIGNS

Half of Americans Expect Costs to Rise After Health Reform



Note: Based on a national poll of 1,521 adults conducted Oct. 16-19.
Source: USA Today/Gallup